Victrex has reported a pre-tax loss of £44 million for the six months to March, a sharp reversal from the £17.2 million profit recorded in the same period last year, and announced plans to cut approximately 10% of its global workforce as part of a drive to restore profitability.
The Lancashire-based polymer manufacturer, which employs around 1,100 people worldwide, said the majority of the redundancies will be implemented in the third quarter of 2026 and will primarily affect central operations rather than customer-facing roles. The company has not disclosed the exact number of posts to be eliminated. Severance costs from the cuts will be included within up to £10 million in exceptional charges for the current financial year.
Job cuts and financial performance
The swing into loss was driven largely by a £60.6 million non-cash impairment charge on a manufacturing facility in Panjin, China. Underlying pre-tax profit, which strips out such one-off items, fell by 18% to £19 million, down from £23.2 million a year earlier. Group revenue edged up 0.8% to £147.1 million, supported by a 5.9% increase in sales volumes to 2,137 tonnes.
Gross margin narrowed to 41.7% from 44.1%, which the company attributed to a softer average selling price within its Sustainable Solutions division, weaker Medical sales, and currency fluctuations. On a net basis, Victrex recorded a loss of £32.3 million for the half-year, compared with net income of £15.2 million in the prior year, while basic loss per share was £0.37, against earnings of £0.174 a year earlier.
Impairment on Chinese facility
The £60.6 million impairment on the Panjin plant is the single largest factor behind the statutory loss. Victrex said the charge is linked to a process technology fault that has capped the facility’s output below its nameplate capacity of 1,500 metric tonnes. Although the plant is located in what the company describes as its fastest-growing region, it is expected to remain “significantly loss making and cash negative in the current year”. The company stressed it remains committed to the site.
The impairment forms part of total exceptional items of £63 million for the half-year. In addition to the China writedown and the severance costs, Victrex warned it will record a further £10 million in non-cash exceptional charges in the second half of the financial year as a result of its project and portfolio review.
Profit improvement plan and market headwinds
Victrex is pushing ahead with a “Profit Improvement Plan” designed to simplify the business, sharpen customer focus, and achieve at least £10 million in annualised cost savings from fiscal year 2027, with early benefits expected in the second half of the current financial year. James Routh, who took over as chief executive in January 2026, said the company had “not adapted quickly enough to changed market conditions” and needed to “relentlessly focus on improving our execution”. Routh added that establishing a high-performance leadership team would help drive the next phase of sustainable growth. A Capital Markets Day is scheduled for September 2026 to outline medium-term ambitions.
The company faces several headwinds. It warned that the ongoing Middle East conflict poses potential implications for global demand and energy costs, though it had no material impact in the first half, and the company said energy hedging and supplier contracts would provide protection in the second half. Currency fluctuations were projected to hit profit before tax by approximately £7 million to £8 million in the previous financial year. Within its Medical segment, revenue fell 9% to £27.6 million, affected by destocking in Spine applications, though the company noted signs of stabilisation. Revenue from sustainable products accounted for 46% of total revenue in the first half, down from 55% a year earlier, largely due to lower Medical and Automotive sales.
For the full financial year 2026, Victrex expects underlying pre-tax profit to be between £42 million and £44 million, below the company-compiled consensus estimate of £46.6 million. It also anticipates a slightly lower gross margin than the 45.3% recorded in the prior year.
Shares in Victrex fell 4.8% in early trading on Monday, 11 May. The stock is down 10.1% year-to-date and has underperformed the FTSE 350 by 1.2% over the past week. Analysts give Victrex a consensus rating of “Hold”, with an average price target of GBX 750, suggesting an upside of approximately 27.3% from its current price. The company’s price-to-earnings ratio stands at 18.52, below the market average of 44.23 and the Basic Materials sector average of 22.63.
